IHC analysis of the anti-apoptotic marker (BCL-2) declared that the percentages of BCL-2-immunostained tumor cells (red arrows) in FeO NPs-DE-treated and Gem-treated mice were 37.6 ± 0.75% and 80.6 ± 0.55%, respectively, relative to the PBS-treated group (Fig. 7d). This evidence concerns the gene BCL2 and neoplasm.